^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KITE-363

    i
    Other names: KITE-363, KITE363, KITE 363
    Associations

    News

    Trials
    Company:
    Gilead
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    13d
    KT-US-499-0150: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=247, Recruiting, Kite, A Gilead Company | Phase classification: P1 --> P1/2 | N=114 --> 247
    Phase classification • Enrollment change
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CSF2 (Colony stimulating factor 2) • IL15 (Interleukin 15) • IL1R1 (Interleukin 1 receptor, type I) • IL7 (Interleukin 7)
    |
    cyclophosphamide • fludarabine IV • KITE-363
    24d
    A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases (clinicaltrials.gov)
    P1, N=52, Not yet recruiting, Kite, A Gilead Company
    New P1 trial • Pan tumor
    |
    cyclophosphamide • fludarabine IV • KITE-363
    2ms
    A Phase 1 Open-label, Multiregional, Multicenter, BasketnStudy Evaluating the Safety and Efficacy of KITE-363, annAutologous Anti-CD19/CD20 CAR T-cell Therapy innParticipants with Relapsed/Refractory AutoimmunenNeurologic Diseases (ACTRN12625001346460)
    P1, N=52, Not yet recruiting, Kite, A Gilead Company
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • KITE-363
    3ms
    KT-US-499-0150: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=114, Recruiting, Kite, A Gilead Company | Trial completion date: May 2027 --> Oct 2027 | Trial primary completion date: May 2027 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CSF2 (Colony stimulating factor 2) • IL15 (Interleukin 15) • IL1R1 (Interleukin 1 receptor, type I) • IL7 (Interleukin 7)
    |
    cyclophosphamide • fludarabine IV • KITE-363
    6ms
    A Study of KITE-363 in Participants With Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=52, Enrolling by invitation, Kite, A Gilead Company | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • KITE-363
    7ms
    Study of Kite-363 in participants with difficult to treat autoimmune diseases, evaluating efficacy and safety. (ACTRN12625000707460)
    P1, N=52, Not yet recruiting, Kite, A Gilead Company
    New P1 trial • Pan tumor
    |
    cyclophosphamide • fludarabine IV • KITE-363
    7ms
    A Study of KITE-363 in Participants With Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=52, Not yet recruiting, Kite, A Gilead Company
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • KITE-363
    9ms
    KT-US-499-0150: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=114, Recruiting, Kite, A Gilead Company | Trial primary completion date: Jul 2026 --> May 2027 | Trial completion date: Jul 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CSF2 (Colony stimulating factor 2) • IL15 (Interleukin 15) • IL1R1 (Interleukin 1 receptor, type I) • IL7 (Interleukin 7)
    |
    cyclophosphamide • fludarabine IV • KITE-363
    1year
    Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov)
    P=N/A, N=1000, Enrolling by invitation, Kite, A Gilead Company | N=700 --> 1000
    Enrollment change
    |
    Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • KITE-363 • anitocabtagene autoleucel (CART-ddBCMA)
    almost2years
    Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov)
    P2, N=700, Enrolling by invitation, Kite, A Gilead Company | Trial completion date: Mar 2041 --> Dec 2040 | Trial primary completion date: Mar 2041 --> Dec 2040
    Trial completion date • Trial primary completion date
    |
    Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • KITE-222 • KITE-363 • KITE-439 • KITE-585 • KITE-718
    almost2years
    KT-US-499-0150: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=114, Recruiting, Kite, A Gilead Company | Trial completion date: Jan 2027 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV • KITE-363
    almost2years
    KT-US-499-0150: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=114, Recruiting, Kite, A Gilead Company | Trial completion date: Jan 2041 --> Jan 2027 | Trial primary completion date: Apr 2024 --> Jul 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV • KITE-363